ALK-Abelló A/S (AKBLF)

Market Cap	5.87B
Revenue (ttm)	827.03M
Net Income (ttm)	135.76M
Shares Out	n/a
EPS (ttm)	0.61
PE Ratio	43.21
Forward PE	31.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	407
Open	25.95
Previous Close	25.31
Day's Range	25.95 - 25.95
52-Week Range	19.90 - 27.03
Beta	0.59
RSI	48.92
Earnings Date	May 6, 2025

About ALK-Abelló

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food. It also provides consumer healt...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1923
• Employees: 2,753
• Stock Exchange: OTCMKTS
• Ticker Symbol: AKBLF

Financial Performance

In 2024, ALK-Abelló's revenue was 5.54 billion, an increase of 14.78% compared to the previous year's 4.82 billion. Earnings were 815.00 million, an increase of 67.70%.

Financial numbers in DKK